IP Verse

Il-2 Dosage Regimen For Treating Systemic Lupus Erythematosus - EP3443979

The patent EP3443979 was granted to Assistance Publique Hpitaux DE Paris on May 27, 2020. The application was originally filed on Mar 9, 2012 under application number EP18179669A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3443979

ASSISTANCE PUBLIQUE HPITAUX DE PARIS
Application Number
EP18179669A
Filing Date
Mar 9, 2012
Status
Granted And Under Opposition
Apr 24, 2020
Grant Date
May 27, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANFeb 26, 2021MEWBURN ELLISADMISSIBLE

Patent Citations (28) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0109748
DESCRIPTIONEP0118617
DESCRIPTIONEP0136489
DESCRIPTIONEP0200280
DESCRIPTIONUS4530787
DESCRIPTIONUS4604377
DESCRIPTIONUS4656132
DESCRIPTIONUS4748234
DESCRIPTIONUS4752585
OPPOSITIONEP0262802
OPPOSITIONUS2011150826
OPPOSITIONUS5466447
OPPOSITIONWO02078624
OPPOSITIONWO2005007121
OPPOSITIONWO2007084651
OPPOSITIONWO2009112502
OPPOSITIONWO2010049438
OPPOSITIONWO2010085495
OPPOSITIONWO2012065212
OPPOSITIONWO9114444
OPPOSITIONWO9918992
OPPOSITIONWO9926660
SEARCHEP0262802
SEARCHUS5466447
SEARCHWO02078624
SEARCHWO2007084651
SEARCHWO2010049438
SEARCHWO2012065212

Non-Patent Literature (NPL) Citations (57) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AGNELLO et al., "A role for hepatitis C virus infection in type II cryoglobulinemia", N Engl J Med, (19920000), vol. 327, pages 1490 - 5, XP002993373-
DESCRIPTION- AHMADZADEH M; SA ROSENBERG, "IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients", Blood, (20060000), vol. 107, pages 2409 - 14-
DESCRIPTION- BOYER O; SAADOUN D; ABRIOL J et al., "CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis", Blood, (20040000), vol. 103, pages 3428 - 30-
DESCRIPTION- CACOUB P; POYNARD T; GHILLANI P et al., "Extrahepatic manifestations of chronic hepatitis C", Arthritis Rheum, (19990000), vol. 42, pages 2204 - 12-
DESCRIPTION- CHAPUT et al., "Identification of CD8+CD20+Foxp3+ suppressive T cells in colorectal cancer tissue", Gut, (20090000), vol. 58, pages 520 - 9-
DESCRIPTION- CHARLES et al., "Clonal expansion of immunoglobulin M+CD27+B cells inHCV-associated mixes cryoglobulinemia", Blood, (20080000), vol. 111, pages 1344 - 56-
DESCRIPTION- CONCANNON et al., "Genetics of type 1A diabetes", N Engl J Med, (20090000), vol. 360, pages 1646 - 54-
DESCRIPTION- DONADA et al., "Systemic manifestation and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia", Blood, (19980000), vol. 91, pages 2062 - 6-
DESCRIPTION- DUBOIS; DUBOIS, Arch Intern Med, (19160000), vol. 17, page 863-
DESCRIPTION- GILLIS S; J WATSON, "Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line", J Exp Med, (19800000), vol. 152, pages 1709 - 19-
DESCRIPTION- GRINBERG-BLEYER Y; A BAEYENS; S YOU; R ELHAGE; G FOURCADE; S GREGOIRE et al., "IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells", J Exp Med, vol. 207, pages 1871 - 8, XP002650094-
DESCRIPTION- IMAN et al., "Approximations of the Critical Region of the Friedman Statistic", Communications in Statistics Part a-Theory and Methods, (19800000), vol. 9, pages 571 - 95-
DESCRIPTION- LANDAU DA; ROSENZWAJG M; SAADOUN D; TREBEDEN-NEGRE H; KLATZMANN D; CACOUB P, "Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis", Arthritis Rheum, (20080000), vol. 58, pages 2897 - 907-
DESCRIPTION- LENZI M; FRISONI M; MANTOVANI V et al., "Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia", Blood, (19980000), pages 2062 - 6-
DESCRIPTION- LUNEL et al., "Cryoglobulinemia in chronic liver disease: role of hepatitis C virus and liver damage", Gastroenterology, (19940000), vol. 106, pages 1291 - 300-
DESCRIPTION- NAGASAKA et al., "Cryoglobulinemia in Japanese patients with chronic hepatitis C virus infection: host genetic and virological study", J Med Virol, (20010000), vol. 65, pages 52 - 7-
DESCRIPTION- PAPIERNIK M; ML DE MORAES; C PONTOUX; F VASSEUR; C PENIT, "Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency", Int Immunol, (19980000), vol. 10, pages 371 - 8-
DESCRIPTION- SAADOUN D; RESCHE RIGON M; SENE D et al., "Rituximab plus Peg-interferon-alpha/ ribavirin compared with Peg-interferonalpha/ribavirin in hepatitis C-related mixed cryoglobulinemia", Blood, (20100000), vol. 116, pages 326 - 34-
DESCRIPTION- SAADOUN D; ROSENZWAJG M; LANDAU D; PIETTE JC; KLATZMANN D; CACOUB P, "Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis", Blood, (20080000), vol. 111, pages 5334 - 41-
DESCRIPTION- "Whittington and Faulds Interleukin-2", A review of its pharmacological properties and therapeutic use in patients with cancer Drugs, (19930000), vol. 46, no. 3, pages 446 - 514-
DESCRIPTION- WILLIAMS MA; AJ TYZNIK; MJ BEVAN, "Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells", Nature, (20060000), vol. 441, pages 890 - 3-
DESCRIPTION- GOREVIC PD; KASSAB HJ; LEVO Y et al., "Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients", Am J Med, (19800000), vol. 69, doi:doi:10.1016/0002-9343(80)90390-3, pages 287 - 308, XP026371996
DESCRIPTION- GILLIS S; KA SMITH, "Long term culture of tumour-specific cytotoxic T cells", Nature, (19770000), vol. 268, doi:doi:10.1038/268154a0, pages 154 - 6, XP000670220
DESCRIPTION- TANIGUCHI T; MATSUI H; FUJITA T; TAKAOKA C; KASHIMA N; YOSHIMOTO R; HAMURO J, "Structure and expression of a cloned cDNA for human interleukin-2", Nature, (19830000), vol. 302, doi:doi:10.1038/302305a0, pages 305 - 10, XP002558027
DESCRIPTION- ZHANG H; KS CHUA; M GUIMOND; V KAPOOR; MV BROWN; TA FLEISHER et al., "Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells", Nat Med, (20050000), vol. 11, doi:doi:10.1038/nm1312, pages 1238 - 43, XP055044996
DESCRIPTION- MOSTELLER RD, "Simplified calculation of body-surface area", N Engl J Med, (19870000), vol. 317, doi:doi:10.1056/NEJM198710223171717, page 1098, XP008156553
DESCRIPTION- MALEK TR, "The biology of interleukin-2", Annu Rev Immunol, (20080000), vol. 26, doi:doi:10.1146/ANNUREV.IMMUNOL.26.021607.090357, pages 453 - 79, XP002687867
OPPOSITION- A Alice Long, Cerosaletti Karen, Bollyky Paul L, Tatum Megan, Shilling Heather, Zhang Sheng, Zhang Zhong-Yin, Pihoker Catherine, Sanda Srinath, Greenbaum Carla, Buckner Jane H, "Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4 Regulatory T-Cells of Type 1 Diabetic Subjects", Diabetes, American Diabetes Association, US, US , (20100201), vol. 59, doi:10.2337/db09-0694, ISSN 0012-1797, pages 407 - 415, XP055590405-
OPPOSITION- Anonymous, "History of Changes for Study: NCT01353833 Dose-effect Relationship of Low-dose IL-2 Versus Placebo in Type 1 Diabetes (DFIL2)", clinicaltrials.gov, (20120420), XP055979525-
OPPOSITION- Anonymous, "PROLEUKIN® (aldesleukin)", Prometheus Laboratories Inc., (20120701), Prometheus Laboratories Inc., URL: https://proleukin.com, (20221109), XP055979400-
OPPOSITION- BOYMAN ONUR ET AL, "Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.", (20061201), vol. 6, no. 12, pages 1323 - 1331, XP002457767-
OPPOSITION- George C. Tsokos, "Mechanisms of disease for the clinician: systemic lupus erythematosus", THE NEW ENGLED JOURNAL OF MEDICINE, (20111201), vol. 365, no. 22, pages 2110 - 2121, XP055979497-
OPPOSITION- Grinberg-Bleyer Y, Baeyens A, You S, et al, "IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20100801), vol. 207, no. 9, ISSN 0022-1007, pages 1871 - 1878, XP002650094-
OPPOSITION- Jacquelyn A. Hank, Jean Surfus, Jacek Gan, Mark Albertini, Mary Lindstrom, Joan H. Schiller, Kirsten M. Hotton, Masoud Khorsand, Paul M. Sondel, "Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations", Clinical Cancer Research, American Association for Cancer Research, United States, United States , (19990201), pages 281 - 289, Clinical Cancer Research, URL: http://clincancerres.aacrjournals.org/content/clincanres/5/2/281.full.pdf, (20190521), XP055590425-
OPPOSITION- Jens Y Humrich,, "Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractpry SLE ", Ann. Rheum. Dis., (20150101), vol. 74, no. 4, pages 791 - 792, XP055979510-
OPPOSITION- Makoto Miyara, Zahir Amoura, Christophe Parizot, Cecile Badoual, Karim Dorgham, Salim Trad, Dominique Nochy, Patrice Debre, Jean-Charles Piette And Guy Gorochov, "Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus", The Journal of · Immunology, (20050101), vol. 175, pages 8392 - 8400, XP055979489-
OPPOSITION- MALEK THOMAS R, ET AL, "CD4 regulatory T cells prevent lethal autoimmunity in IL-2R.beta.-deficient mice: Implications for the nonredundant function of IL-2", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20020801), vol. 17, no. 2, ISSN 1074-7613, pages 167 - 178, XP002579301-
OPPOSITION- Michelle Petri, Jill Buyon Mimi Kim, "CLASSIFICATION AND DEFINITION OF MAJOR FLARES IN SLR SLINICAL TRIALS ", LUPUS, (19990101), vol. 8, pages 685 - 691, XP055979505-
OPPOSITION- Tang, Et Al., "Central role of defective interleukin-2 production in triggering islet autoimmune destruction", Immunity, (20080101), vol. 28, no. 5, pages 687 - 697, XP055813498-
OPPOSITION- BOMBARDIER C; GLADMAN D D; UROWITZ M B; CARON D; CHANG C H; COMM PROGNOSIS STUD SYST LUPUS ERYTHEMATOSUS (CAN), "DERIVATION OF THE SLEDAI A DISEASE ACTIVITY INDEX FOR LUPUS PATIENTS", Arthritis & Rheumatism, Wiley InterScience, US, US , (19920101), vol. 35, no. 6, doi:10.1002/art.1780350606, ISSN 0004-3591, pages 630 - 640, XP009147421
OPPOSITION- Talal Norman, Fischbach Michael, "Interleukins in Experimental Autoimmune Disease", Reproductive Sciences in Animal Conservation, New York, NY, Springer New York, (19830101), vol. 166, pages 105 - 115, doi:10.1007/978-1-4757-1410-4_11, ISSN 0065-2598, ISBN 978-1-4939-0820-2, XP055979341
OPPOSITION- Miyasaka, N. ; Nakamura, T. ; Russell, I.J. ; Talal, N., "Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY., SAN DIEGO, CA., US, US , (19840401), vol. 31, no. 1, doi:10.1016/0090-1229(84)90195-8, ISSN 0090-1229, pages 109 - 117, XP022958938
OPPOSITION- Griffiths, B. Mosca, M. Gordon, C., "Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL REUMATOLOGY, BAILLIERE TINDALL, LONDON, GB, GB , (20051001), vol. 19, no. 5, doi:10.1016/j.berh.2005.03.010, ISSN 1521-6942, pages 685 - 708, XP005056667
OPPOSITION- Petri Michelle, "Review of Classification Criteria for Systemic Lupus Erythematosus", RHEUMATIC DISEASES CLINICS OF NORTH AMERICA., W.B. SAUNDERS, PHILADELPHIA, PA., US, US , (20050501), vol. 31, no. 2, doi:10.1016/j.rdc.2005.01.009, ISSN 0889-857X, pages 245 - 254, XP055979305
OPPOSITION- CRISPIN JOSE C , MARTINEZ ARACELI, ALCOCER-VARELA JORGE, "Quantification of regulatory T cells in patients with systemic lupus erythematosus.", JOURNAL OF AUTOIMMUNITY, LONDON, GB, GB , (20031101), vol. 21, no. 3, doi:10.1016/S0896-8411(03)00121-5, ISSN 0896-8411, pages 273 - 276, XP002549909
OPPOSITION- Agnes Hartemann, Gilbert Bensimon, Christine A Payan, Sopie Jacqueminet, Olivier Bourron, Nathalie Nicolas, Michele Fonfrede, Michelle Rosenzwajg, Claude Bernard, David Katzmann, "Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial", The lancet / Diabetes & Endocrinology, Elsevier, UK, UK , (20131201), vol. 1, no. 4, doi:10.1016/S2213-8587(13)70113-X, ISSN 2213-8587, pages 295 - 305, XP055590288
OPPOSITION- Jun Yamanouchi, Dan Rainbow, Pau Serra, Sarah Howlett, Kara Hunter, Valerie E S Garner, Andrea Gonzalez-Munoz, Jan Clark, Riitta Veijola, Rose Cubbon, Show-Ling Chen, Raymond Rosa, Anne Marie Cumiskey, David V Serreze, Simon Gregory, Jane Rogers, Paul A Lyons, Barry Healy, Luc J Smink, John A Todd, Laurence B Peterson, Linda S Wicker, Pere Santamaria, "Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity", Nature Genetics, Nature America, Inc., (20070301), vol. 39, no. 3, doi:10.1038/ng1958, ISSN 10614036, pages 329 - 337, XP055084274
OPPOSITION- He Jing; Zhang Xia; Wei Yunbo; Sun Xiaolin; Chen Yaping; Deng Jun; Jin Yuebo; Gan Yuzhou; Hu Xin; Jia Rulin; Xu Chuanhui; Hou Zhaohua; Leong Yew Ann; Zhu Lei; Feng Jinhong; An Yuan; Jia Yuan; Li Chun; Liu Xu; Ye Hua; Ren Limin; Li Ru; Yao Haihong; Li Yuhui; Chen Shi; Zhang Xuewu; Su Yin; Guo Jianping; Shen Nan; Morand Eric F; Yu Di; Li Zhanguo, "Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus", Nature Medicine, Nature Publishing Group US, New York, New York, (20160808), vol. 22, no. 9, doi:10.1038/nm.4148, ISSN 1078-8956, pages 991 - 993, XP037922194
OPPOSITION- David Klatzmann, Abul K. Abbas, "The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases", Nature Reviews Immunology, Nature Publishing Group UK, London, London, vol. 15, no. 5, doi:10.1038/nri3823, ISSN 1474-1733, pages 283 - 294, XP055408855
OPPOSITION- SAADOUN D, ET AL, "Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20111201), vol. 365, no. 22, doi:10.1056/NEJMoa1105143, ISSN 0028-4793, pages 2067 - 2077, XP002674646
OPPOSITION- KORETH J, ET AL, "Interleukin-2 and regulatory T cells in graft-versus-host disease", The New England journal of medicine, Massachusetts Medical Society, US, US , (20111211), vol. 365, no. 22, doi:10.1056/NEJMoa1108188, ISSN 0028-4793, pages 2055 - 2066, XP002674647
OPPOSITION- HUMRICH JENS Y ET AL, "Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20100101), vol. 107, no. 1, doi:10.1073/pnas.0903158107, ISSN 0027-8424, pages 204 - 209, XP002787802
OPPOSITION- Christian Klein, Inja Waldhauer, Valeria G. Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Danielle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, Martine Stihle, Sabine Lang, Michaele Roemmele, Thomas Hofer, Erwin Van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina De Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus Van Dongen, Ekkehard Moessner, Pablo Umaña, "Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines", OncoImmunology, (20170304), vol. 6, no. 3, doi:10.1080/2162402X.2016.1277306, page e1277306, XP055489641
OPPOSITION- Jyh‐Hong Lee; Li‐Chieh Wang; Yu‐Tsan Lin; Yao‐Hsu Yang; Dong‐Tsamn Lin; Bor‐Luen Chiang, "Inverse correlation between CD4+ regulatory T‐cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus", Cancer research, Wiley-Blackwell Publishing Ltd., GB, GB , (20060117), vol. 117, no. 2, doi:10.1111/j.1365-2567.2005.02306.x, ISSN 0019-2805, pages 280 - 286, XP071275537
OPPOSITION- d'Hennezel Eva; Kornete Mara; Piccirillo Ciriaco A, "IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease", Journal of Translational Medicine, BioMed Central, (20101108), vol. 8, no. 1, doi:10.1186/1479-5876-8-113, ISSN 1479-5876, pages 1 - 11, XP021088835
SEARCH- GRINBERG-BLEYER YENKEL ET AL, "IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells", JOURNAL OF EXPERIMENTAL MEDICINE, (201008), vol. 207, no. 9, ISSN 0022-1007, pages 1871 - 1878, XP002650094 [Y] 1-15 * see abstract and page 1877 right col. *-
SEARCH- HUMRICH JENS Y ET AL, "Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (201001), vol. 107, no. 1, ISSN 0027-8424, pages 204 - 209, XP002787802 [Y] 1-15 * see abstract, page 206 right col., Fig.6, page 209 "material and methods" *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents